FDA Approves Qiagen CDx for Vectibix Colorectal Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Qiagen's Therascreen KRAS RGQ PCR companion test to pick out best responders to Amgen's colorectal cancer drug Vectibix (panitumumab).

Simultaneously, the agency also approved late last week Vectibix in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer. The latest approval converts the accelerated approval for Vectibix into full approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.